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Background: Many cancer patients seek complementary and alternative medicine (CAM) including acupuncture to
manage their cancer-related symptoms or side effects of treatments. Acupuncture is used to manage cancer pain
and improve quality of life (QoL). This study aimed to conduct a preliminary study on a case series to evaluate the
feasibility of acupuncture for treating cancer pain and to collect preliminary data on the effectiveness of
acupuncture in treating cancer pain and improving QoL.
Methods: A semi-standardized acupuncture treatment comprising one to three treatment sessions (20–30 minutes
per session) per week for 8 weeks was provided by four licensed acupuncturists, who had more than 5 years of
clinical experience, at the University Health Center. The European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire (EORTC QLQ-C3) and a visual analogue scale (VAS) for pain rating were used as
the outcome measures to assess pain and QoL. Data were collected at baseline, immediately after 2, 4, 6, and 8
weeks of treatment and at 4 weeks after treatment completion (week 12).
Results: Two males and five females with a median age of 66 years (range: 44–71 years) completed the study. For the
VAS, the percentage of improvement ranged between 18% and 95%. The baseline mean raw score was reduced from
51 mm to 36 mm at the end of week 8 and to 23 mm at the end of week 12. The percentage of overall QoL
improvement ranged between 20% and 100%. The mean raw score for QoL improved with time. The baseline score
was increased from 55 to 69 at the end of treatment (week 8) and to 73 after the follow-up (week 12).
Conclusions: This pilot study on a case series showed that acupuncture might be beneficial for reducing pain and
improving QoL in cancer patients.Background
Cancer is the second leading cause of mortality in the
United States [1], and 41.24% of men and women born
in the United States will be diagnosed with some type of
cancer during their lifetime [2]. Although modern ther-
apies for cancer have improved life expectancy, the man-
agement of this complex disease [3] and improvement of
quality of life (QoL) of patients, especially in managing
cancer-related pain, are still limited. Cancer pain is fre-
quently reported among patients, with 53% of patients
experiencing pain, and one-third experiencing severe to
moderate levels of acute or chronic pain [4]. The occur-
rence of pain in cancer patients increases the risk for* Correspondence: sivaramavinjamury@scuhs.edu
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reproduction in any medium, provided the orpsychological disorders (e.g., anxiety, depression, and
suicidal ideation) [5], that distract patients from their
daily activities (e.g., ability to concentrate) [6]. In
addition, the cause of pain is not limited to the physio-
logical etiology, but also arises through side effects of
standard treatment modalities like drugs, surgery, radio-
therapy, and chemotherapy [3].
Opioids are currently used in cancer pain management
[7]. The World Health Organization has described a
three-step analgesic ladder on how to effectively admin-
ister opioids for chronic cancer pain, with the main goal
being to prohibit pain by giving high doses of the drugs
around-the-clock [8,9]. However, up to 20% of patients
are resistant to opioids [10], and of those who are not re-
sistant, many choose not to have treatments that involve
narcotic substances because of the various side effects.
The common short-term side effects are constipation,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Some patients prefer to endure the pain rather than con-
tinue to use opioids [12]. For clinicians, the most
concerning side effect is respiratory depression, especially
in high-risk patients, such as elderly patients, obese
patients, patients with a history of sleep apnea, and pa-
tients with impaired pulmonary, renal, cardiac, or hepatic
function [11]. Long-term administration of opioids can in-
duce tolerance [13], endocrine dysfunction [14], and
multisystem adverse effects [15].
Complementary and alternative medicine (CAM) is cur-
rently used in conjunction with standard cancer treat-
ments, with 66.5% of cancer survivors reporting use of
CAM, 43.3% of those reported used within one year [16].
Regarding the range, 25–84% of cancer patients seek
CAM at least once during their treatments to manage
symptoms or side effects [17]. Acupuncture studies have
shown potential in alleviating pain and functional disor-
ders associated with specific types of cancers [15]. Al-
though acupuncture was found to have analgesic effects,
there are few rigorous studies to support its efficacy [18].
Acupuncture can boost immunity by increasing the num-
bers of leukocytes, B-cells, immunoglobulins, and erythro-
cytes, as well as the activity of NK cells [19-21]. It can also
alleviate the side effects of chemotherapy or radiotherapy
[22], and treat depressive symptoms with equivalent or
better efficacy than conventional antidepressants, such as
amitriptyline, maprotiline, and mianserin [23,24]. Research
on cancer pain is seldom addressed in CAM institutions
[25], although some case series are available to warrant in-
vestigation [26]. This study aimed to conduct a case series
study to investigate the effects of acupuncture on cancer
patients recruited from a CAM institution.
Methods
This study was registered on November 15, 2006 at Clinical
Trial.gov with the registration number NCT00401063.
Participant recruitment
Over a period of 12 months, flyers were distributed to
the community, including 20 local MDs, three oncolo-
gists, two cancer support groups, five chiropractors and
acupuncturists, 10–15 local businesses, two local librar-
ies, and the local YMCA. In addition, electronic versions
of the flyers were periodically distributed to the campus
community, comprising approximately 700 people.
This study incorporated specific inclusion and exclu-
sion criteria. The participants were older than 18 years,
and of either sex. The participants had to have a con-
firmed diagnosis of cancer by an oncologist, and a base-
line pain score of 3 or more on a 0–10 rating scale. The
participants’ pain was evaluated as the results of under-
lying cancer or cancer treatments. The participants were
ambulatory, had platelet counts of 50,000 or greater, andobtained permission from their physicians to participate
in the study. Participants were excluded from the study
if they had received acupuncture treatment in the past 4
weeks, if they were unable to obtain permission from
their treating physicians, if they were unwilling to sign
informed consent, or if they were involved in any
current litigation. They were also excluded if they were
simultaneously infected with HIV/hepatitis B virus, if
they had neutropenia defined as an absolute neutrophil
count of <1000/mL, or if they had any kind of bleeding
disorders where the platelet count was <50,000.
The Southern California University of Health Sciences
Institutional Review Board approved the study. It was
also registered at the clinicaltrials.gov website. All eli-
gible participants signed an informed consent form prior
to clinical screening.
Study intervention
In this case series study, the acupuncture treatment was
semi-standardized for all patients, and based on the type
of cancer and the patient’s condition. However, the points
Zusanli (ST36) and Sanyinjiao (SP6) were common to all
patients, because qi and yin will be deficient in all cancer
patients, regardless of the type of cancer [24]. The fre-
quency of the treatments varied from one to three treat-
ment sessions per week for 8 weeks. Four licensed acu
puncturists, who had more than 5 years of clinical experi-
ence, provided the acupuncture treatments. Same clinician
treated each participant throughout the study period.
SeirinW acupuncture needles of 0.25 mm in diameter and
40 mm in length were used. Each treatment session lasted
20–30 minutes. Electroacupuncture was optional, and was
based on the participant’s need as determined by the
acupuncturist. All the treatments were provided at the
University Health Center at Southern California Univer-
sity of Health Sciences.
Outcome measures
The European Organization for Research and Treatment
of Cancer Quality of Life Questionnaire (EORTC QLQ-
C3) and a visual analogue scale (VAS) for pain were used
in this study. Both of these measures were shown to be
valid and reliable for cancer patients [27-29]. The
EORTC QLQ-C3 is a 30-item questionnaire used to assess
health-related QoL, which includes five functional scales
(physical, role, emotional, cognitive, and social) and eight
single-item symptom scales (fatigue, nausea and vomiting,
pain, dyspnea, insomnia, appetite loss, constipation, and
diarrhea). All functional and symptom scales are 4-point
scales (e.g., 1=not at all to 4=very much) with a total range
from 0–100. QoL was assessed by a 7-point scale from
“very poor” to “excellent”. The descriptions of the scores
are as follows: high functional scale score represents a
high and healthy level of functioning; high general health
Table 1 Demographic characteristics of the participants









Non-Hodgkins lymphoma 1 14
Breast cancer 4 57
Pancreatic cancer 1 14
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represents a high level of symptomatology. A standard
VAS was used to evaluate the participant’s perception of
pain. Each participant was provided with a horizontal 100-
mm line anchored with the descriptions “no pain” and
“worst pain” at each end. The participants marked the line
at their current levels of pain, and the evaluator used a
ruler to measure the patients’ marks. All participants were
asked to complete both outcome measures at the begin-
ning of the study, as well as at the end of weeks 2, 4, 6,
and 8. The participants filled in the forms prior to their
treatments at each time-point. There was also an on-site
follow up evaluation at 4 weeks after the last treatment
(end of week 12). No information on participant–provider
interactions or patient expectations was collected.
Data analysis
The demographic characteristics of the patients were de-
scribed using the mean and standard deviation (SD). The
percentages of improvement from baseline in the VAS,
and EORTC QLQ and general health status/QoL at the
end of week 8 and the end of week 12 (after follow-up)
were calculated for individual cases. The percentages were
calculated by dividing the difference between the baseline
and endpoint scores by the baseline score. The VAS and
fatigue and general health status within the EORTC QLQ
were presented as the mean ± SD. Values of P<0.05 were
considered statistical significant. A longitudinal regression
analysis (random mixed-effects model) was also per-
formed on an exploratory basis for each outcome measure
to describe the overall trend and the rate of change over
time (considering variations in the baseline values of all
measurements) starting from baseline.
Results
Twenty participants were screened, and 10 participants
were included. The rest of the screened participants did
not match our inclusion criteria (n=7), could not commit
to the study treatment protocol (n=2), or did not receive
approval from their oncologist/physicians owing to theirTable 2 Percent improvements in the VAS, physical function,









1 18 35 67 0
2 −36 NA 22 NA
3 −39 −21 8 15
4 33 NA 0 NA
5 78 78 22 44
6 95 96 8 8
7 65 37 8 0
NOTE: Positive values for the VAS indicate improvement (decrease) of pain and negadvanced condition (n=1). Of the 10 participants, seven
successfully completed the study, two dropped out be-
cause of natural progression and exacerbation of their dis-
eases, and one dropped out because of no improvement at
the end of four treatments. Of the seven participants who
completed the study, five were female and two were male.
The median age was 66 years (range: 44–71 years). Four
of the seven participants were diagnosed with breast can-
cer, and the other three were diagnosed with leukemia,
non-Hodgkin’s lymphoma, and pancreatic cancer, respect-
ively (Table 1).
For the VAS, the percentage of improvement varied
between 18% and 95% at the end of week 8 in five cases,
whereas the pain worsened in two cases (Table 2). How-
ever, the mean raw score indicated an overall improve-
ment in pain. The baseline mean raw score of 51±29.5
mm was reduced to 36±28.8 mm at the end of week 8
and to 23±20.3 mm at the end of week 12 (Table 3). For
the EORTC QLQ, moderate or no improvement was no-
ticed in the subscales of physical function, emotional
function, and cognitive and social function. The per-
centage of improvement at the end of week 8 and the
end of week 12 varied between 0% and 100% in individ-
ual cases. For the general health status/QoL, a subscaleemotional function and QoL
Emotional function General health (QoL)








0 14 −13 −25
0 NA 50 NA
12 38 20 20
100 NA 100 NA
−11 0 50 50
450 300 25 38
18 −45 25 −25
ative values indicate worsening (increase) of pain. NA: Not available.


























































Vinjamury et al. Chinese Medicine 2013, 8:15 Page 4 of 6
http://www.cmjournal.org/content/8/1/15within the EORTC QLQ, the percentage of improvement
varied between 20% and 100%. However, one participant
reported decreases in QoL and general health status at
the end of week 8 (−12%) and the end of week 12
(−25%) (Table 2). The mean raw score of general health
and QoL improved with time. The baseline score of
55±22.0 increased to 66±22.9 at the end of treatment
(week 8) and to 73±23.1 after follow-up (week 12), indi-
cating an overall improvement in QoL (Table 3). Fatigue
was the only symptom showing improvement, since the
mean raw score of fatigue was reduced from 49.2±24.7
to 31.74±17.4 at the end of week 8 and to 24.44±14.8 at
the end of week 12. Figure 1 illustrates the changes in
the mean scores of the general health status/QoL, VAS,
and fatigue with time.
The results from the exploratory longitudinal regres-
sion analysis showed that there was a significant associ-
ation (R2=83%, P=0.02) between the VAS pain score and
the visit time, suggesting that the VAS score was signifi-
cantly decreased (lower score means less pain) over
time. For the QoL scales, the results were calculated forFigure 1 Mean scores of the general health status/QoL, VAS, and fatigdifferent subscales of the EORTC QLQ: physical func-
tion, emotional function, cognitive and social function,
symptom scales, and global health status/QoL. No major
change in the physical function, emotional function, and
cognitive and social function scores was found, except in
two patients. No major change in the symptom scales
for any participants occurred, although slight negative
changes in the symptom scales were noted in some
participants. There was an overall positive change in all
but one participant for the normal health status/QoL
subscale by week 8. This positive change continued at
the end of week 12 in all but one participant. Statistical
analysis using the random mixed-effects model approach
showed a significant association (R2=70%, P=0.02) be-
tween the general health status/QoL score and the visit
time, suggesting that the general health status/QoL score
was significantly increased with time. No significant side
effects were reported by the participants throughout the
study. However, one participant reported aggravation of
pain, burning, and dizziness after the first treatment and
during the second visit. These symptoms subsided on
their own within 24 h and did not recur. No other side
effects or adverse events were reported.
Discussion
The results of this case series study indicate that the re-
cruitment rate was acceptable (50%). Our best referral
sources were cancer support groups and participants
within our trial, who believed that they had benefits from
participating in the study. Cancer support groups are often
led by cancer survivors, and their meetings occur in a
non-threatening atmosphere, function as a discussion
forum for cancer patients and survivors, and provideue.
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ences of fellow members. Our recruitment was difficult
because of our limited budget for advertisement. Further-
more, our recruitment team consisted of student workers,
who were trained to screen and properly conduct the in-
formed consent process to ensure trust between the inves-
tigating team and the participant. It remains unknown
whether some participants did not sign up because of the
lack of experience of the screening and recruiting
personnel. Both financial and human resources are very
crucial for successful recruitment.
Referral from oncologists was hindered by long dis-
tances between the patients’ homes and the study center.
The oncologists were informed of the concurrent treat-
ments of their patients. The cancer patients were
reassured by the consent from their oncologists/physi-
cians. All eligible patients with consent from their oncol-
ogists and physicians were willing to participate in our
study. Thus, we plan to strengthen our communication
with local oncologists to increase their recognition of
our program and eventually aid the recruitment in fu-
ture studies.
Positive changes with respect to both cancer pain and
QoL were observed. A reduction in pain and an im-
provement in general health were noted at the end of
week 8, which continued to improve (end of week 12)
even after the treatment was discontinued.
Although these results are consistent with previous
studies [30-32], no firm conclusions could be drawn from
our findings because of the limitations inherent in a case
series design including a small sample size and lack of a
control group. Furthermore, we were unable to obtain
complete follow-up data of all participants and interpret
the data toward any specific type of cancer pain or QoL is-
sues. It is also recommended to set a minimum score for
the QoL scale as an eligibility criterion, to avoid a ceiling
effect when assessing differences in QoL measures.
Conclusion
In this pilot study, the results of the EORTC QLQ-C3 and
VAS showed that acupuncture might be beneficial for redu-
cing pain and improving QoL in cancer patients.
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